Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2001 Sep;47:1787–1793.

Current management of acute ischemic stroke. Part 1: Thrombolytics and the 3-hour window.

A M Herd 1
PMCID: PMC2018568  PMID: 11570304

Abstract

OBJECTIVE: To help family physicians who care for patients with acute stroke or who are involved in planning service delivery or resource allocation to understand recent developments in acute stroke care. QUALITY OF EVIDENCE: A MEDLINE search indicated that most data were derived from well designed, randomized, double-blind, placebo-controlled trials, including all the largest international studies and large systematic reviews. MAIN MESSAGE: Treatment of acute stroke with tissue plasminogen activator seems beneficial for certain patients with certain kinds of stroke. Because thrombolytic therapy is not without risk and requires substantial resources, it should be administered only by physicians trained in its use and in centres with the necessary experience and resources. Because time is important, an organized and efficient system of stroke care with collaboration between hospital and prehospital care providers and help from ordinary citizens is essential. CONCLUSION: Management of acute stroke is an emerging discipline; many potential therapies are still experimental.

Full Text

The Full Text of this article is available as a PDF (171.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke. 1997 Aug;28(8):1530–1540. doi: 10.1161/01.str.28.8.1530. [DOI] [PubMed] [Google Scholar]
  2. Albers G. W., Bates V. E., Clark W. M., Bell R., Verro P., Hamilton S. A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000 Mar 1;283(9):1145–1150. doi: 10.1001/jama.283.9.1145. [DOI] [PubMed] [Google Scholar]
  3. Buchan A. M., Barber P. A., Newcommon N., Karbalai H. G., Demchuk A. M., Hoyte K. M., Klein G. M., Feasby T. E. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology. 2000 Feb 8;54(3):679–684. doi: 10.1212/wnl.54.3.679. [DOI] [PubMed] [Google Scholar]
  4. Clark W. M., Albers G. W., Madden K. P., Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000 Apr;31(4):811–816. doi: 10.1161/01.str.31.4.811. [DOI] [PubMed] [Google Scholar]
  5. Clark W. M., Wissman S., Albers G. W., Jhamandas J. H., Madden K. P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999 Dec 1;282(21):2019–2026. doi: 10.1001/jama.282.21.2019. [DOI] [PubMed] [Google Scholar]
  6. Donnan G. A., Davis S. M., Chambers B. R., Gates P. C., Hankey G. J., McNeil J. J., Rosen D., Stewart-Wynne E. G., Tuck R. R. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA. 1996 Sep 25;276(12):961–966. [PubMed] [Google Scholar]
  7. Gomez C. R., Malkoff M. D., Sauer C. M., Tulyapronchote R., Burch C. M., Banet G. A. Code stroke. An attempt to shorten inhospital therapeutic delays. Stroke. 1994 Oct;25(10):1920–1923. doi: 10.1161/01.str.25.10.1920. [DOI] [PubMed] [Google Scholar]
  8. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., Boysen G., Bluhmki E., Höxter G., Mahagne M. H. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA. 1995 Oct 4;274(13):1017–1025. [PubMed] [Google Scholar]
  9. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998 Oct 17;352(9136):1245–1251. doi: 10.1016/s0140-6736(98)08020-9. [DOI] [PubMed] [Google Scholar]
  10. Haley E. C., Jr, Lewandowski C., Tilley B. C. Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med. 1997 Nov;30(5):676–682. doi: 10.1016/s0196-0644(97)99996-0. [DOI] [PubMed] [Google Scholar]
  11. Hill M. D., Barber P. A., Demchuk A. M., Sevick R. J., Newcommon N. J., Green T., Buchan A. M. Building a "brain attack" team to administer thrombolytic therapy for acute ischemic stroke. CMAJ. 2000 May 30;162(11):1589–1593. [PMC free article] [PubMed] [Google Scholar]
  12. Kothari R., Jauch E., Broderick J., Brott T., Sauerbeck L., Khoury J., Liu T. Acute stroke: delays to presentation and emergency department evaluation. Ann Emerg Med. 1999 Jan;33(1):3–8. doi: 10.1016/s0196-0644(99)70431-2. [DOI] [PubMed] [Google Scholar]
  13. Libman R. B., Wirkowski E., Alvir J., Rao T. H. Conditions that mimic stroke in the emergency department. Implications for acute stroke trials. Arch Neurol. 1995 Nov;52(11):1119–1122. doi: 10.1001/archneur.1995.00540350113023. [DOI] [PubMed] [Google Scholar]
  14. Lott C., Hennes H. J., Dick W. Stroke--a medical emergency. J Accid Emerg Med. 1999 Jan;16(1):2–7. doi: 10.1136/emj.16.1.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. O'Connor R. E., McGraw P., Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med. 1999 Jan;33(1):9–14. doi: 10.1016/s0196-0644(99)70411-7. [DOI] [PubMed] [Google Scholar]
  16. Osborn T. M., LaMonte M. P., Gaasch W. R. Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies. Ann Emerg Med. 1999 Aug;34(2):244–255. doi: 10.1016/s0196-0644(99)70240-4. [DOI] [PubMed] [Google Scholar]
  17. Pancioli A. M., Broderick J., Kothari R., Brott T., Tuchfarber A., Miller R., Khoury J., Jauch E. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA. 1998 Apr 22;279(16):1288–1292. doi: 10.1001/jama.279.16.1288. [DOI] [PubMed] [Google Scholar]
  18. Selman W. R., Tarr R., Landis D. M. Brain attack: emergency treatment of ischemic stroke. Am Fam Physician. 1997 Jun;55(8):2655-62, 2665-6. [PubMed] [Google Scholar]
  19. Steiner T., Bluhmki E., Kaste M., Toni D., Trouillas P., von Kummer R., Hacke W. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc Dis. 1998 Jul-Aug;8(4):198–203. doi: 10.1159/000015851. [DOI] [PubMed] [Google Scholar]
  20. Toni D., Fiorelli M., Bastianello S., Sacchetti M. L., Sette G., Argentino C., Montinaro E., Bozzao L. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology. 1996 Feb;46(2):341–345. doi: 10.1212/wnl.46.2.341. [DOI] [PubMed] [Google Scholar]
  21. Wardlaw J. M., Warlow C. P., Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet. 1997 Aug 30;350(9078):607–614. doi: 10.1016/s0140-6736(97)03022-5. [DOI] [PubMed] [Google Scholar]
  22. von Kummer R., Meyding-Lamadé U., Forsting M., Rosin L., Rieke K., Hacke W., Sartor K. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol. 1994 Jan;15(1):9–18. [PMC free article] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES